NCT01609790 2022-07-21Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsNational Cancer Institute (NCI)Phase 2 Completed137 enrolled 13 charts
NCT01648348 2018-05-23Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI)Phase 1/2 Completed116 enrolled 17 charts